(Q45274595)

English

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study

scientific article published in March 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

phase II clinical trial

0 references

ovarian carcinoma

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Scott Miller

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Heinz-Josef Lenz

3

object named as

Heinz-Josef Lenz

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Agustin A Garcia

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

John A Blessing

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Kathleen M Darcy

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Robert S Mannel

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Nader Husseinzadeh

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Gynecologic Oncology Group

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

96

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

810-817

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Salvage therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

The activity and expression of thymidine phosphorylase in human solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Real time quantitative PCR

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

A novel method for real time quantitative RT-PCR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.037

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2004.11.037

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45274595&oldid=2072296969"